2020
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience
Sawas A, Ma H, Kuruvilla J, Lue JK, Deng C, Marchi E, Montanari F, Cheng B, Savage KJ, Villa D, Crump M, Connors JM, O’Connor O. Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. Leukemia & Lymphoma 2020, 61: 3014-3017. PMID: 32720828, DOI: 10.1080/10428194.2020.1795161.Peer-Reviewed Original ResearchLow dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series
Ma H, Cheng B, Montanari F, Lue JK, Deng C, Marchi E, Connor O, Sawas A. Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. Therapeutic Advances In Hematology 2020, 11: 2040620720947340. PMID: 33062232, PMCID: PMC7534065, DOI: 10.1177/2040620720947340.Peer-Reviewed Original ResearchAutologous stem cell transplantClassical Hodgkin lymphomaR cHLRefractory classical Hodgkin lymphomaStable diseasePartial responseComplete responseHodgkin's lymphomaPatient populationToxicity profileHigher disease control rateMedian progression-free survivalAlanine transaminase elevationClinical benefit rateLeast equivalent efficacyDisease control rateProgression-free survivalRetrospective case seriesStem cell transplantTolerable toxicity profileFavorable safety profileFavorable toxicity profileContinuous lenalidomideCreatinine elevationTransaminase elevation
2018
Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience
Sawas A, Kuruvilla J, Lue J, Deng C, Amengual J, Montanari F, Savage K, Elgedawe H, Villa D, Crump M, Connors J, O'Connor O. Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience. Blood 2018, 132: 2907. DOI: 10.1182/blood-2018-99-117251.Peer-Reviewed Original ResearchAutologous stem cell transplantProgression-free survivalRefractory Hodgkin lymphomaComplete response rateDose limiting toxicitiesHigh-dose chemotherapyOverall response rateHodgkin's lymphomaBrentuximab vedotinOverall survivalDay 1Partial responseMedian numberDose levelsPrior autologous stem cell transplantResponse rateAutologous stem cell transplantationSeattle GeneticsPhase II dosePhysician's choice chemotherapyPrior radiation therapyPrior systemic therapyLong-term respondersSubset of patientsEvidence of relapse
2017
Treatment and Prognosis
Montanari F, Diefenbach C. Treatment and Prognosis. Molecular Pathology Library 2017, 197-219. DOI: 10.1007/978-3-319-68094-1_9.Peer-Reviewed Original ResearchHodgkin's lymphomaPositron emission tomographyRisk assessment toolClinical prognostic scoring systemsFirst-line therapyPrognostic scoring systemRisk-adapted approachGoal of treatmentNew treatment strategiesPossibility of cureLong-term toxicityAssessment toolRelapsed patientsPediatric patientsPrognostic factorsPromising immunotherapyStandard treatmentTherapeutic decisionsTreatment strategiesNew therapiesTherapeutic strategiesPatientsScoring systemEmission tomographyTreatment standards
2015
Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F, Diefenbach CS. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy. Clinical Advances In Hematology And Oncology 2015, 13: 518-24. PMID: 26351815.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaCHL microenvironmentAutologous stem cell transplantLong-term disease controlTumor microenvironmentHeterogeneous inflammatory infiltratesReed-Sternberg (HRS) tumor cellsFirst-line therapyStem cell transplantAdvanced-stage patientsNew biologic insightsRelapsed patientsCell transplantInflammatory infiltrateHodgkin's lymphomaClinical trialsTherapeutic strategiesTumor growthTumor cellularityDisease controlNovel antitumor strategyBiologic insightsHRS cellsTumor cellsAntitumor strategy
2014
Relapsed Hodgkin Lymphoma: Management Strategies
Montanari F, Diefenbach C. Relapsed Hodgkin Lymphoma: Management Strategies. Current Hematologic Malignancy Reports 2014, 9: 284-293. PMID: 24942298, PMCID: PMC4909353, DOI: 10.1007/s11899-014-0220-7.Peer-Reviewed Original ResearchConceptsStem cell transplantAutologous stem cell transplantHigh-dose chemotherapyCell transplantHodgkin's lymphomaAllogeneic hematopoietic stem cell transplantHematopoietic stem cell transplantChemotherapy-refractory diseaseRelapsed Hodgkin lymphomaTransient disease controlElderly patient populationFirst-line therapyManagement of patientsBrentuximab vedotinDose chemotherapyRefractory diseaseComplete responseConventional therapyPatient populationNovel therapiesNew agentsPatientsDisease controlTransplantTherapy
2011
Hodgkin’s Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,
Diefenbach C, Sabado R, Brooks C, Baquero-Buitrago J, Cruz C, Vengco I, Montanari F, Marchi E, Scotto L, Cirrito T, Bergstein I, O'Connor O. Hodgkin’s Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,. Blood 2011, 118: 3737. DOI: 10.1182/blood.v118.21.3737.3737.Peer-Reviewed Original ResearchHodgkin Reed-Sternberg cellsSL-401CD123 expressionHodgkin's lymphomaComplete responseTreatment strategiesLymphoma cell linesMyeloid leukemiaCell linesAutologous stem cell transplantMalignant Hodgkin Reed-Sternberg (HRS) cellsCell viabilityPrimary refractory diseaseRefractory Hodgkin lymphomaSecond-line chemotherapySecond-line therapyHigh expressionEffective therapeutic optionStem cell transplantReceptor α expressionAcute myeloid leukemiaChronic myeloid leukemiaClassical Hodgkin lymphomaPotential treatment strategyNovel treatment strategies